Literature DB >> 21788250

Rat Ace allele variation determines susceptibility to AngII-induced renal damage.

Jelena Kamilic1, Inge Hamming, A Titia Lely, Ron Korstanje, Ute Schulze, Wilfred J Poppinga, Anthony J Turner, Nicola E Clarke, Harry van Goor, Gerjan J Navis.   

Abstract

INTRODUCTION: Ace b/l polymorphism in rats is associated with differential tissue angiotensin-converting enzyme (ACE) expression and activity, and susceptibility to renal damage. Same polymorphism was recently found in outbred Wistar rat strain with b allele accounting for higher renal ACE, and provided a model for studying renin-angiotensin-aldosterone system (RAAS) response behind the innate high or low ACE conditions.
METHODS: We investigated the reaction of these alleles on chronic angiotensin II (AngII) infusion. Wistar rats were selected to breed male homozygotes for the b (WU-B) or l allele (WU-L) (n = 12). For each allele, one group (n = 6) received AngII infusion via an osmotic minipump (435 ng/kg/min) for 3 weeks. The other group (n = 6) served as a control.
RESULTS: WU-B had higher ACE activity at baseline then WU-L. Interestingly, baseline renal ACE2 expression and activity were higher in WU-L. AngII infusion induced the same increase in blood pressure in both genotypes, no proteinuria, but caused tubulo-interstitial renal damage with increased α-SMA and monocyte/macrophage influx only in WU-B (p < 0.05). Low ACE WU-L rats did not develop renal damage.
CONCLUSION: AngII infusion causes proteinuria-independent renal damage only in rats with genetically predetermined high ACE while rats with low ACE seemed to be protected against the detrimental effect of AngII. Differences in renal ACE2, mirroring those in ACE, might be involved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788250      PMCID: PMC3356861          DOI: 10.1177/1470320311415886

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  49 in total

Review 1.  Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats.

Authors:  M Challah; E Villard; M Philippe; A Ribadeau-Dumas; B Giraudeau; P Janiak; J P Vilaine; F Soubrier; J B Michel
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

2.  Strain differences in angiotensin-converting enzyme and angiotensin II type I receptor expression. Possible implications for experimental chronic renal transplant failure.

Authors:  Annemieke Smit-van Oosten; Robert H Henning; Harry van Goor
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2002-03       Impact factor: 1.636

3.  Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.

Authors:  Atsushi Shiota; Koichi Yamamoto; Mitsuru Ohishi; Yuji Tatara; Miyuki Ohnishi; Yoshihiro Maekawa; Yoshihiro Iwamoto; Masao Takeda; Hiromi Rakugi
Journal:  Hypertens Res       Date:  2010-02-26       Impact factor: 3.872

4.  Polymorphism of the angiotensin-converting enzyme (ACE) and angiotesinogen (AGT) genes and their associations with blood pressure and carotid artery intima media thickness among healthy Finnish young adults--the Cardiovascular Risk in Young Finns Study.

Authors:  Md Shaheenul Islam; Terho Lehtimäki; Markus Juonala; Mika Kähönen; Nina Hutri-Kähönen; Katariina Kainulainen; Helena Miettinen; Leena Taittonen; Kimmo Kontula; Jorma S A Viikari; Olli T Raitakari
Journal:  Atherosclerosis       Date:  2006-01-04       Impact factor: 5.162

5.  Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II.

Authors:  Denis Feliers; Senthil Duraisamy; Jeffrey L Barnes; Goutam Ghosh-Choudhury; Balakuntalam S Kasinath
Journal:  Am J Physiol Renal Physiol       Date:  2004-11-30

6.  The influence of the ACE ( I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus.

Authors:  P T Luik; K Hoogenberg; M N Kerstens; B J Beusekamp; P E De Jong; R P F Dullaart; G J Navis
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

7.  Angiotensin-converting enzyme and angiotensin II receptor subtype 2 genotypes in type 1 diabetes and severe hypoglycaemia requiring emergency treatment: a case cohort study.

Authors:  Ulrik Pedersen-Bjergaard; Søren L Nielsen; Kamran Akram; Hans Perrild; Børge G Nordestgaard; Hugh E Montgomery; Stig Pramming; Birger Thorsteinsson
Journal:  Pharmacogenet Genomics       Date:  2009-11       Impact factor: 2.089

8.  Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension.

Authors:  R Kreutz; N Hübner; D Ganten; K Lindpaintner
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

9.  Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.

Authors:  A H Danser; M A Schalekamp; W A Bax; A M van den Brink; P R Saxena; G A Riegger; H Schunkert
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

Review 10.  Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis.

Authors:  Masaru Iwai; Masatsugu Horiuchi
Journal:  Hypertens Res       Date:  2009-05-22       Impact factor: 3.872

View more
  2 in total

1.  A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease.

Authors:  Keng-Thye Woo; Hui-Lin Choong; Kok-Seng Wong; Han-Kim Tan; Marjorie Foo; Fook-Chong Stephanie; Evan Jc Lee; Vathsala Anantharaman; Grace Sl Lee; Choong-Meng Chan
Journal:  World J Nephrol       Date:  2013-11-06

2.  Correlations between ACE single nucleotide polymorphisms and prognosis of patients with septic shock.

Authors:  Xin-Man Dou; Hui-Juan Cheng; Ling Meng; Lin-Lin Zhou; Yi-Hong Ke; Li-Ping Liu; Yu-Min Li
Journal:  Biosci Rep       Date:  2017-04-28       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.